Breakthrough in Lung Cancer: Imfinzi’s FDA Approval for Limited-Stage SCLC Patients
JYOTI AstraZeneca’s (AZ) Imfinzi (durvalumab) has received approval from the US Food and Drug Administration (FDA) for treating adults…
lung cancer
AEGEAN Phase 3 Trial Results: A New Era in Lung Cancer Therapy
The recent recommendation by NICE for AstraZeneca’s Imfinzi (durvalumab) in combination with chemotherapy marks a significant advancement for…